BACKGROUND AND PURPOSE: To compare the outcome from adjuvant and delayed radiotherapy (RT) after surgery in patients with benign cerebral meningioma. PATIENTS AND METHODS: Between March 1953 and January 2001, 92 patients with benign cerebral meningioma (WHO grade I) were treated with surgery. Forty-eight patients underwent gross total resection (GTR), and 44 patients underwentsubtotal resection (STR). Treatments were classified as GTR (n = 48), STR+adjuvant RT (n = 12), STR alone (n = 32). The prognostic factors were assessed as, gender, the Karnofsky performance score (KPS) (> or =90 vs. <90), the extent of surgery, and adjuvant or delayed RT. The endpoints analyzed were progression-free survival (PFS) and overall survival (OS). Overall survival curve of the study population is compared with the age-adjusted expected survival curve for the US population born in 1970. RESULTS: The median follow-up was 7.7 years. The 5-year PFS and OS rates for all patients were 65 and 93%, respectively. The 5-year PFS rates in patients treated with GTR and STR were 77 and 52%, respectively (P = 0.02). Patients treated with STR+adjuvant RT had significantly better PFS (91%) at 5 years than with STR alone (38%) (P = 0.0005). Gender showed no statistically significant impact on either PFS or OS (P > 0.05). However, multivariate analysis showed the KPS to have a statistically significant effect on OS (P = 0.02). The OS rate was the same across all three treatment groups. The age-adjusted expected survival curve for the US population born in 1970 lay within the confidence intervals for the overall survival curve of the study population. CONCLUSIONS: Although OS was not affected, adjuvant RT appeared to significantly reduce tumor progression. However, only a prospective randomized trial can adequately determine whether adjuvant or delayed radiotherapy is the better approach in patients with subtotally resected benign meningioma.
RCT Entities:
BACKGROUND AND PURPOSE: To compare the outcome from adjuvant and delayed radiotherapy (RT) after surgery in patients with benign cerebral meningioma. PATIENTS AND METHODS: Between March 1953 and January 2001, 92 patients with benign cerebral meningioma (WHO grade I) were treated with surgery. Forty-eight patients underwent gross total resection (GTR), and 44 patients underwent subtotal resection (STR). Treatments were classified as GTR (n = 48), STR+adjuvant RT (n = 12), STR alone (n = 32). The prognostic factors were assessed as, gender, the Karnofsky performance score (KPS) (> or =90 vs. <90), the extent of surgery, and adjuvant or delayed RT. The endpoints analyzed were progression-free survival (PFS) and overall survival (OS). Overall survival curve of the study population is compared with the age-adjusted expected survival curve for the US population born in 1970. RESULTS: The median follow-up was 7.7 years. The 5-year PFS and OS rates for all patients were 65 and 93%, respectively. The 5-year PFS rates in patients treated with GTR and STR were 77 and 52%, respectively (P = 0.02). Patients treated with STR+adjuvant RT had significantly better PFS (91%) at 5 years than with STR alone (38%) (P = 0.0005). Gender showed no statistically significant impact on either PFS or OS (P > 0.05). However, multivariate analysis showed the KPS to have a statistically significant effect on OS (P = 0.02). The OS rate was the same across all three treatment groups. The age-adjusted expected survival curve for the US population born in 1970 lay within the confidence intervals for the overall survival curve of the study population. CONCLUSIONS: Although OS was not affected, adjuvant RT appeared to significantly reduce tumor progression. However, only a prospective randomized trial can adequately determine whether adjuvant or delayed radiotherapy is the better approach in patients with subtotally resected benign meningioma.
Authors: Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers Journal: Neuro Oncol Date: 2012-03-09 Impact factor: 12.300
Authors: Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum Journal: J Neurosurg Date: 2015-01 Impact factor: 5.115
Authors: Kamila Nowak-Choi; Joshua D Palmer; James Casey; Ameet Chitale; Ingrid Kalchman; Elizabeth Buss; Scott W Keith; Sarah E Hegarty; Mark Curtis; Charalambos Solomides; Wenyin Shi; Kevin Judy; David W Andrews; Christopher Farrell; Maria Werner-Wasik Journal: J Neurooncol Date: 2021-01-09 Impact factor: 4.130
Authors: Kira Marie Voß; Dorothee Cäcilia Spille; Cristina Sauerland; Eric Suero Molina; Caroline Brokinkel; Werner Paulus; Walter Stummer; Markus Holling; Astrid Jeibmann; Benjamin Brokinkel Journal: J Neurooncol Date: 2017-05-19 Impact factor: 4.130
Authors: Brian M Andersen; G Elizabeth Pluhar; Charles E Seiler; Michelle R Goulart; Karen S SantaCruz; Melissa M Schutten; Joyce P Meints; M Gerard O'Sullivan; R Timothy Bentley; Rebecca A Packer; Stephanie A Thomovsky; Annie V Chen; Dominik Faissler; Wei Chen; Matthew A Hunt; Michael R Olin; John R Ohlfest Journal: Cancer Res Date: 2013-03-07 Impact factor: 12.701
Authors: Leland Rogers; Peixin Zhang; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; David Brachman; Joseph M Jenrette; John De Groot; Joseph A Bovi; Maria Werner-Wasik; Jonathan P S Knisely; Minesh P Mehta Journal: J Neurosurg Date: 2017-10-06 Impact factor: 5.115